|
Video: What is a Stock Split?
|
|
Aprea Therapeutics is a clinical-stage biopharmaceutical company. Co.'s primary synthetic lethality product candidate is ATRN-119, a clinical-stage small molecule inhibitor of ataxia telangiectasia and Rad3-related (ATR), a kinase that plays a critical role in DNA damage response (DDR). Co. is targeting WEE1, a kinase that is a key regulator of multiple phases of the cell cycle. Co.'s primary WEE1 inhibitor product candidate is ATRN-1051. In addition, Co. has a preclinical research program directed at a second-generation ATR inhibitor, ATRN-354. Finally, Co. also has an early preclinical research program, which is aimed at identification of inhibitors of a distinct protein involved in DDR. According to our APRE split history records, Aprea Therapeutics has had 1 split. | |
|
Aprea Therapeutics (APRE) has 1 split in our APRE split history database. The split for APRE took place on February 13, 2023. This was a 1 for 20 reverse split, meaning for each 20 shares of APRE owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 50 share position following the split.
When a company such as Aprea Therapeutics conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the APRE split history from start to finish, an original position size of 1000 shares would have turned into 50 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Aprea Therapeutics shares, starting with a $10,000 purchase of APRE, presented on a split-history-adjusted basis factoring in the complete APRE split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
10/04/2019 |
|
End date: |
04/26/2024 |
|
Start price/share: |
$381.40 |
|
End price/share: |
$5.20 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-98.64% |
|
Average Annual Total Return: |
-60.98% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$136.29 |
|
Years: |
4.56 |
|
|
|
Date |
Ratio |
02/13/2023 | 1 for 20 |
|
|